Abstract
Purpose: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. Methods: In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1. Results: The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713–0.769]) in the taxane arm and 0.748 [0.722–0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789–0.834] vs. 0.772 [0.751–0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003). Conclusions: Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm.
| Original language | English |
|---|---|
| Pages (from-to) | 1-9 |
| Number of pages | 9 |
| Journal | Quality of Life Research |
| DOIs | |
| Publication status | Accepted/In press - Aug 12 2016 |
Fingerprint
Keywords
- Breast cancer
- EQ-5D
- Health-related quality of life
- Randomized controlled trial
- S-1
- Taxane
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
Cite this
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer : comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. / Shiroiwa, T.; Fukuda, T.; Shimozuma, K.; Mouri, M.; Hagiwara, Y.; Doihara, Hiroyoshi; Akabane, H.; Kashiwaba, M.; Watanabe, T.; Ohashi, Y.; Mukai, H.
In: Quality of Life Research, 12.08.2016, p. 1-9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term health status as measured by EQ-5D among patients with metastatic breast cancer
T2 - comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
AU - Shiroiwa, T.
AU - Fukuda, T.
AU - Shimozuma, K.
AU - Mouri, M.
AU - Hagiwara, Y.
AU - Doihara, Hiroyoshi
AU - Akabane, H.
AU - Kashiwaba, M.
AU - Watanabe, T.
AU - Ohashi, Y.
AU - Mukai, H.
PY - 2016/8/12
Y1 - 2016/8/12
N2 - Purpose: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. Methods: In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1. Results: The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713–0.769]) in the taxane arm and 0.748 [0.722–0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789–0.834] vs. 0.772 [0.751–0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003). Conclusions: Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm.
AB - Purpose: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. Methods: In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1. Results: The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713–0.769]) in the taxane arm and 0.748 [0.722–0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789–0.834] vs. 0.772 [0.751–0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003). Conclusions: Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm.
KW - Breast cancer
KW - EQ-5D
KW - Health-related quality of life
KW - Randomized controlled trial
KW - S-1
KW - Taxane
UR - http://www.scopus.com/inward/record.url?scp=84982084149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982084149&partnerID=8YFLogxK
U2 - 10.1007/s11136-016-1388-1
DO - 10.1007/s11136-016-1388-1
M3 - Article
SP - 1
EP - 9
JO - Quality of Life Research
JF - Quality of Life Research
SN - 0962-9343
ER -